Related Experiment Video
Updated: Jul 17, 2026

Surfactant Depletion Combined with Injurious Ventilation Results in a Reproducible Model of the Acute Respiratory Distress Syndrome (ARDS)
Published on: April 7, 2021
[Experience with surfactant used in the treatment of patients with lingering pneumonia]
Abstract:
Two groups of patients were followed up. Group 1 consisted of 70 patients receiving inhaled Surfactant-BL through a bronchoalveolar nebulizer. Group 2 (control) included 40 patients with lingering pneumonia untreated with the surfactant. Physical studies and determination of the intensity of cough were made in all the patients on admission and 2 weeks later. In this study, there were no adverse reactions caused by surfactant in patients with lingering pneumonia. Following 14 days of therapy, there was a reduction in the intensity of cough in the study group patients as compared to the controls. Concurrently, the values of external respiration function significantly improved as compared to the baseline ones and the controls. A higher clinical efficiency of treatment was noted in patients with lingering pneumonia treated with surfactant than in those untreated with this agent.
More Related Videos
Related Concept Videos
Breathing
Pneumonia V: Nursing management and Prevention
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed.
Pneumonia IV: Management
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Acute Respiratory Failure-V
Ensure that patients are monitored continuously for their response to therapy, including changes in...
Acute Respiratory Failure-III
Acute Respiratory Failure-II
The underlying physiological abnormalities that contribute to hypoxemic respiratory failure include:

